Beijing GoBroad Healthcare Group

GoBroad Healthcare Group is a leading Chinese clinical research-driven healthcare organization specializing in hematology, oncology, and cell therapy. The group operates a network of specialized hospitals, including Beijing GoBroad Boren Hospital and Shanghai GoBroad Ruijin Hospital, which serve as premier centers for advanced clinical trials and complex medical care. GoBroad integrates clinical services with high-end CRO capabilities, providing a robust platform for the development of innovative therapies such as CAR-T cell treatments. The company is particularly recognized for its expertise in treating refractory hematologic malignancies and conducting investigator-initiated trials (IITs). Backed by major investors like Hillhouse Capital, GoBroad aims to accelerate the translation of basic science into clinical applications within the Chinese healthcare market.